View Older Stories View More Recent Stories

Apr 24, 2023 07:03AM Krystal Biotech (KRYS) Announces Clinical Data on Topical Application of B-VEC
Apr 24, 2023 07:00AM Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
Apr 18, 2023 07:00AM Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest
Apr 13, 2023 07:00AM Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
Mar 6, 2023 07:05AM Krystal Biotech (KRYS) Appoints Catherine Mazzacco to its Board
Mar 6, 2023 07:00AM Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
Mar 2, 2023 07:00AM Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
Feb 27, 2023 07:00AM Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Jan 18, 2023 07:01AM Krystal Biotech (KRYS) Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Jan 18, 2023 07:00AM Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
Jan 9, 2023 08:04AM Krystal Biotech (KRYS) Announces FDA 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC
Jan 9, 2023 08:00AM Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
Dec 14, 2022 05:02PM Krystal Biotech (KRYS) Announces New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
Dec 14, 2022 05:00PM New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
Dec 5, 2022 07:00AM Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
Dec 1, 2022 07:00AM Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference
Nov 23, 2022 07:00AM Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
Nov 17, 2022 07:01AM Krystal's (KRYS) Jeune Aesthetics Reports Positive Durability Results for KB301 in the PEARL-1 Extension Cohort
Nov 17, 2022 07:00AM Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles
Nov 7, 2022 07:00AM Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights
Sep 29, 2022 07:00AM Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference
Sep 21, 2022 04:31PM Krystal Biotech (KRYS) Reports Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC
Sep 21, 2022 04:30PM Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
Sep 21, 2022 04:30PM Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa
Sep 8, 2022 07:00AM Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 18, 2022 05:00PM Krystal Biotech (KRYS) Announces FDA Accepts its Biologics License Application for Dystrophic Epidermolysis Bullosa
Aug 18, 2022 05:00PM FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
Aug 8, 2022 07:00AM Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress
Aug 2, 2022 05:49AM Krystal Biotech (KRYS) Announces FDA Acceptance of KB407 INDA
Aug 1, 2022 06:39PM Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
Aug 1, 2022 07:02AM Krystal Biotech (KRYS) Announces FDA Acceptance of KB407 IND Application
Aug 1, 2022 07:00AM Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
Jul 6, 2022 07:00AM Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
Jun 22, 2022 07:03AM Krystal Biotech (KRYS) Submits BLA to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
Jun 22, 2022 07:00AM Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
Jun 22, 2022 07:00AM Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
Jun 7, 2022 07:00AM Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
May 19, 2022 07:30PM Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
May 9, 2022 04:15PM Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
May 3, 2022 07:00AM Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
Apr 28, 2022 07:00AM Jeune Aesthetics Announces Formation and Members of Scientific Advisory Board
Apr 11, 2022 07:00AM Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
Mar 28, 2022 11:01AM Krystal Biotech (KRYS) Reports Publication of Phase 1 and 2 Clinical Trial of Beremagene Geperpavec
Mar 28, 2022 11:00AM Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
Mar 26, 2022 12:00PM New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
Mar 24, 2022 07:00AM Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
Mar 22, 2022 07:00AM Krystal Biotech's (KRYS) Jeune Aesthetics Reports Positive Clinical Phase 1 Efficacy Results for KB301
Mar 22, 2022 07:00AM Jeune Aesthetics Announces Positive Clinical Phase 1 (PEARL-1 Study) Efficacy Results for KB301, an Investigational Gene-based Treatment Designed to Address the Underlying Biology of Aging Skin
Mar 18, 2022 07:00AM Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
Mar 15, 2022 07:00AM Krystal Biotech (KRYS) Settles with PeriphaGen
View More Recent Stories View Older Stories